Business Context and Reporting Period
This Form 8-K Current Report was filed by Quanterix Corporation (QTRX) on May 14, 2026. The filing primarily addresses executive leadership changes, specifically the appointment of a new Chief Operating Officer and the role transition of the former COO.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel and compensation arrangements rather than financial performance results.
Material Changes
- Executive Appointment: Anthony Catalano was appointed as Chief Operating Officer (COO) effective May 14, 2026.
- Executive Transition: Michael Miller, formerly the COO, has transitioned to the role of Chief Technology and Products Officer.
- Compensation Structure: Mr. Catalano's employment agreement includes a $400,000 annualized base salary, a $50,000 cash sign-on bonus, and an annual performance bonus target of up to 50% of base salary.
- Equity Award: Mr. Catalano received Restricted Stock Units (RSUs) equivalent to 0.30% of the Company's outstanding common stock on his start date, vesting in four equal annual installments.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, outlook, or general risk factors. However, it outlines specific termination contingencies for the new COO:
- Standard Termination: If terminated without Cause or resigns for Good Reason, Mr. Catalano is eligible for six months of base salary, a pro-rated target bonus, and subsidized health benefits.
- Change-in-Control: In the event of a Change-in-Control, the severance period extends to nine months, and all unvested time-based equity awards become fully vested.
Investor Verification Checklist
- Verify the exact number of shares represented by the 0.30% RSU grant based on the share count as of May 14, 2026.
- Review the full Employment Agreement (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason."
- Confirm the impact of the leadership transition on the Company's operational strategy, particularly regarding the recent acquisition of Akoya Biosciences, Inc.
- Monitor future filings for the integration of Mr. Miller's new responsibilities as Chief Technology and Products Officer.